Skip to main content
Premium Trial:

Request an Annual Quote

Illumina and Genomas to Co-Develop SNP, Haplotype Panels for Metabolic Syndrome

NEW YORK, July 20 (GenomeWeb News) - Illumina and Genomas said today that they will co-develop SNP- and haplotype-based gene marker panels related to metabolic syndrome that Illumina may commercialize upon validation.


Genomas said it will use Illumina's BeadStation 500GX benchtop SNP genotyping system to identify diagnostic markers that could be used as PhysioTypes - predictors that Genomas is developing that incorporate haplotypes along with physiological and clinical information and demographic data. Genomas said it will develop PhysioTypes to help predict patient response to exercise, diet, and drug regimens for the treatment of  obesity and the related metabolic syndromes of diabetes and cardiovascular disease.


Upon validation, Illumina said that the SNP and haplotype panels that Genomas discovers "may become available to Illumina customers as products under a royalty-bearing license."


Additional terms of the agreement were not provided.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.